



**ATALANTE** : A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab

- First patient screened in France on 26th September
- First patient randomized on 7th October
- 4 randomized patients in France (17th October)
- Safety run-in for the first 40 patients
- Submission in other countries from November 2016
- **Investigator's meeting in Lisbon on Friday 28<sup>th</sup> October at 7pm (Sheraton Hotel)**